JPWO2019038388A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019038388A5 JPWO2019038388A5 JP2020511314A JP2020511314A JPWO2019038388A5 JP WO2019038388 A5 JPWO2019038388 A5 JP WO2019038388A5 JP 2020511314 A JP2020511314 A JP 2020511314A JP 2020511314 A JP2020511314 A JP 2020511314A JP WO2019038388 A5 JPWO2019038388 A5 JP WO2019038388A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- mva
- her2
- cells
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 255
- 102000038129 antigens Human genes 0.000 claims description 254
- 108091007172 antigens Proteins 0.000 claims description 254
- 108090001123 antibodies Proteins 0.000 claims description 236
- 102000004965 antibodies Human genes 0.000 claims description 236
- 206010028980 Neoplasm Diseases 0.000 claims description 217
- 101700025368 ERBB2 Proteins 0.000 claims description 210
- 102100016662 ERBB2 Human genes 0.000 claims description 209
- 101710037934 QRSL1 Proteins 0.000 claims description 209
- 238000001990 intravenous administration Methods 0.000 claims description 199
- 201000011510 cancer Diseases 0.000 claims description 190
- 239000000203 mixture Substances 0.000 claims description 169
- 150000007523 nucleic acids Chemical class 0.000 claims description 148
- 108020004707 nucleic acids Proteins 0.000 claims description 143
- 230000035492 administration Effects 0.000 claims description 125
- 210000004881 tumor cells Anatomy 0.000 claims description 120
- 210000001744 T-Lymphocytes Anatomy 0.000 claims description 103
- 102100003729 CD40LG Human genes 0.000 claims description 101
- 108010029697 CD40 Ligand Proteins 0.000 claims description 98
- 230000004083 survival Effects 0.000 claims description 85
- 230000035772 mutation Effects 0.000 claims description 69
- 230000001965 increased Effects 0.000 claims description 63
- 230000027455 binding Effects 0.000 claims description 54
- 150000001413 amino acids Chemical group 0.000 claims description 37
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims description 36
- -1 Dna78 Proteins 0.000 claims description 34
- 206010025650 Malignant melanoma Diseases 0.000 claims description 33
- 201000001441 melanoma Diseases 0.000 claims description 33
- 108010010691 Trastuzumab Proteins 0.000 claims description 28
- 108010042024 pertuzumab Proteins 0.000 claims description 28
- 229960002087 pertuzumab Drugs 0.000 claims description 28
- 241000282414 Homo sapiens Species 0.000 claims description 27
- 229960000575 trastuzumab Drugs 0.000 claims description 26
- 210000000170 Cell Membrane Anatomy 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 22
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 21
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims description 21
- 230000002829 reduced Effects 0.000 claims description 21
- 206010009944 Colon cancer Diseases 0.000 claims description 18
- 101700078950 CD44 Proteins 0.000 claims description 17
- 102100003735 CD44 Human genes 0.000 claims description 17
- 238000006471 dimerization reaction Methods 0.000 claims description 17
- 206010006187 Breast cancer Diseases 0.000 claims description 14
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 238000006366 phosphorylation reaction Methods 0.000 claims description 12
- 230000000865 phosphorylative Effects 0.000 claims description 12
- 230000035755 proliferation Effects 0.000 claims description 12
- 102100008990 CASP8 Human genes 0.000 claims description 11
- 102100005499 PTPRC Human genes 0.000 claims description 11
- 102100019144 CD46 Human genes 0.000 claims description 10
- 102100011842 CEACAM5 Human genes 0.000 claims description 10
- 102100011339 KLK3 Human genes 0.000 claims description 10
- ANZJBCHSOXCCRQ-UHFFFAOYSA-N Mertansine Chemical compound CN1C(=O)CC(OC(=O)C(C)N(C)C(=O)CCS)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)C=CC=C(C)CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-UHFFFAOYSA-N 0.000 claims description 9
- 206010005003 Bladder cancer Diseases 0.000 claims description 8
- 101710004105 DCT Proteins 0.000 claims description 8
- 206010017758 Gastric cancer Diseases 0.000 claims description 8
- 102100013180 KDR Human genes 0.000 claims description 8
- 101710030888 KDR Proteins 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 102100008857 MLANA Human genes 0.000 claims description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims description 8
- 101700059076 PTPRC Proteins 0.000 claims description 8
- 210000002950 fibroblast Anatomy 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 201000011549 stomach cancer Diseases 0.000 claims description 8
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 8
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims description 7
- 102100008450 AFP Human genes 0.000 claims description 7
- 102100005826 CD19 Human genes 0.000 claims description 7
- 101700087100 CD19 Proteins 0.000 claims description 7
- 101710027020 CD46 Proteins 0.000 claims description 7
- 102100003281 CD59 Human genes 0.000 claims description 7
- 101710043956 CEACAM5 Proteins 0.000 claims description 7
- 102100005552 CR1 Human genes 0.000 claims description 7
- 101700042195 CR1 Proteins 0.000 claims description 7
- 102100009368 CR2 Human genes 0.000 claims description 7
- 101700020447 CR2 Proteins 0.000 claims description 7
- 108090000538 Caspase 8 Proteins 0.000 claims description 7
- 102100007097 DCT Human genes 0.000 claims description 7
- 101700036477 FOLH1 Proteins 0.000 claims description 7
- 102100008453 FOLH1 Human genes 0.000 claims description 7
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 claims description 7
- 241000681881 Human mammary tumor virus Species 0.000 claims description 7
- 101710043203 P23p89 Proteins 0.000 claims description 7
- 101700004495 PSG2 Proteins 0.000 claims description 7
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 7
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 7
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 7
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 7
- 206010038389 Renal cancer Diseases 0.000 claims description 7
- 101700038204 TGFA Proteins 0.000 claims description 7
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 7
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 7
- 101710009757 UROD Proteins 0.000 claims description 7
- 201000010982 kidney cancer Diseases 0.000 claims description 7
- 201000007270 liver cancer Diseases 0.000 claims description 7
- 239000001755 magnesium gluconate Substances 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 201000005161 thyroid carcinoma Diseases 0.000 claims description 7
- 102100000189 CD22 Human genes 0.000 claims description 6
- 101700020617 CD22 Proteins 0.000 claims description 6
- 108010013709 Leukocyte Common Antigens Proteins 0.000 claims description 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 6
- 150000002270 gangliosides Chemical class 0.000 claims description 6
- 102100006820 PMEL Human genes 0.000 claims description 5
- 101700035121 PMEL Proteins 0.000 claims description 5
- 102100007096 TYRP1 Human genes 0.000 claims description 5
- 230000012010 growth Effects 0.000 claims description 5
- LVTKHGUGBGNBPL-UHFFFAOYSA-N 3-Amino-1,4-dimethyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 claims description 4
- 102100014001 ABCB1 Human genes 0.000 claims description 4
- 102100006414 AZGP1 Human genes 0.000 claims description 4
- 101710008966 AZGP1 Proteins 0.000 claims description 4
- 108010002367 Anaphase-Promoting Complex-Cyclosome Apc3 Subunit Proteins 0.000 claims description 4
- 101710043900 At2g44920 Proteins 0.000 claims description 4
- 102100011431 BAGE Human genes 0.000 claims description 4
- 108060000856 BAGE Proteins 0.000 claims description 4
- 102100001537 CA9 Human genes 0.000 claims description 4
- 101710040946 CA9 Proteins 0.000 claims description 4
- 101700075287 CASP8 Proteins 0.000 claims description 4
- 102100016493 CD33 Human genes 0.000 claims description 4
- 101700017647 CD33 Proteins 0.000 claims description 4
- 102100019283 CD52 Human genes 0.000 claims description 4
- 108010065524 CD52 Antigen Proteins 0.000 claims description 4
- 102100013391 CD55 Human genes 0.000 claims description 4
- 101710006195 CD55 Proteins 0.000 claims description 4
- 101700073334 CD59 Proteins 0.000 claims description 4
- 102100013075 CDC27 Human genes 0.000 claims description 4
- 101700008359 CDK4 Proteins 0.000 claims description 4
- 102100019398 CDK4 Human genes 0.000 claims description 4
- 102100001891 CTAG1A Human genes 0.000 claims description 4
- 101710004449 CTAG1A Proteins 0.000 claims description 4
- 102000005600 Cathepsins Human genes 0.000 claims description 4
- 108010084457 Cathepsins Proteins 0.000 claims description 4
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 claims description 4
- 102000009508 Cyclin-Dependent Kinase Inhibitor p16 Human genes 0.000 claims description 4
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 claims description 4
- 102100009914 EBAG9 Human genes 0.000 claims description 4
- 101710010062 EBAG9 Proteins 0.000 claims description 4
- 102000003425 EC 1.14.18.1 Human genes 0.000 claims description 4
- 108060008724 EC 1.14.18.1 Proteins 0.000 claims description 4
- 101710038745 EEF1A2 Proteins 0.000 claims description 4
- 102400000102 Eosinophil granule major basic protein Human genes 0.000 claims description 4
- 101700053597 FCER2 Proteins 0.000 claims description 4
- 102100014608 FCER2 Human genes 0.000 claims description 4
- 102000007317 Farnesyltranstransferase Human genes 0.000 claims description 4
- 108010007508 Farnesyltranstransferase Proteins 0.000 claims description 4
- 102000006815 Folate receptors Human genes 0.000 claims description 4
- 108020005243 Folate receptors Proteins 0.000 claims description 4
- 102000020337 GAGE family Human genes 0.000 claims description 4
- 108091015116 GAGE family Proteins 0.000 claims description 4
- 102100001448 GAST Human genes 0.000 claims description 4
- 101700005903 GAST Proteins 0.000 claims description 4
- 102400000921 Gastrin Human genes 0.000 claims description 4
- 108010070675 Glutathione Transferase family Proteins 0.000 claims description 4
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 claims description 4
- 102100003684 HPSE Human genes 0.000 claims description 4
- 101700071120 HSTN Proteins 0.000 claims description 4
- 102100004549 IL13RA2 Human genes 0.000 claims description 4
- 101700033678 KDR Proteins 0.000 claims description 4
- 101710025361 LPGAT1 Proteins 0.000 claims description 4
- 102100018587 LPGAT1 Human genes 0.000 claims description 4
- GKDWRERMBNGKCZ-RNXBIMIWSA-N Little gastrin I Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 GKDWRERMBNGKCZ-RNXBIMIWSA-N 0.000 claims description 4
- 108010010995 MART-1 Antigen Proteins 0.000 claims description 4
- 102100011874 MELTF Human genes 0.000 claims description 4
- 101710042280 MELTF Proteins 0.000 claims description 4
- 101710012533 MLANA Proteins 0.000 claims description 4
- 101700056196 MMP14 Proteins 0.000 claims description 4
- 101700007600 MOK Proteins 0.000 claims description 4
- 102100018023 MOK Human genes 0.000 claims description 4
- 101710005599 MRPL28 Proteins 0.000 claims description 4
- 102100000165 MS4A1 Human genes 0.000 claims description 4
- 101710010909 MS4A1 Proteins 0.000 claims description 4
- 101710034449 MT-CO2 Proteins 0.000 claims description 4
- 102100006044 MUC16 Human genes 0.000 claims description 4
- 102100015262 MYC Human genes 0.000 claims description 4
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 4
- 108010063954 Mucins Proteins 0.000 claims description 4
- 101710043884 Mup15 Proteins 0.000 claims description 4
- 102100002496 NOS2 Human genes 0.000 claims description 4
- 101700049309 NOS2 Proteins 0.000 claims description 4
- 101700042042 NXT1 Proteins 0.000 claims description 4
- 101700045069 ORF4 Proteins 0.000 claims description 4
- 102000009890 Osteonectin Human genes 0.000 claims description 4
- 108010077077 Osteonectin Proteins 0.000 claims description 4
- 102100004854 PDZK1IP1 Human genes 0.000 claims description 4
- 101710008157 PDZK1IP1 Proteins 0.000 claims description 4
- 102100006759 PRAME Human genes 0.000 claims description 4
- 108060006580 PRAME Proteins 0.000 claims description 4
- 101710040930 PTGS2 Proteins 0.000 claims description 4
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims description 4
- 101700044827 RNMT Proteins 0.000 claims description 4
- 102100004228 SART1 Human genes 0.000 claims description 4
- 101710037092 SART1 Proteins 0.000 claims description 4
- 102000035572 SSX family Human genes 0.000 claims description 4
- 108091018015 SSX family Proteins 0.000 claims description 4
- 102100019667 STAT3 Human genes 0.000 claims description 4
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 4
- 102100017517 SUB1 Human genes 0.000 claims description 4
- 101700063611 SUB1 Proteins 0.000 claims description 4
- 102100009560 TNFRSF6B Human genes 0.000 claims description 4
- 101710022317 TNFRSF6B Proteins 0.000 claims description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N Tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 4
- 102000006747 Transforming growth factor alpha Human genes 0.000 claims description 4
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 4
- 108060000903 beta Catenin Proteins 0.000 claims description 4
- 102000015735 beta Catenin Human genes 0.000 claims description 4
- 101700013556 entH Proteins 0.000 claims description 4
- 108010048134 estramustine-binding protein Proteins 0.000 claims description 4
- 108010066264 gastrin 17 Proteins 0.000 claims description 4
- 101710031154 gene 11 Proteins 0.000 claims description 4
- 101710017840 gene 15 Proteins 0.000 claims description 4
- 108010037536 heparanase Proteins 0.000 claims description 4
- 108040003607 interleukin-13 receptor activity proteins Proteins 0.000 claims description 4
- 101710030893 kdrl Proteins 0.000 claims description 4
- 108090000015 mesothelin Proteins 0.000 claims description 4
- 102000003735 mesothelin Human genes 0.000 claims description 4
- 108010042121 probasin Proteins 0.000 claims description 4
- 239000003488 releasing hormone Substances 0.000 claims description 4
- 108010010447 trophoblastin Proteins 0.000 claims description 4
- 230000035899 viability Effects 0.000 claims description 4
- 101700029306 ANG1 Proteins 0.000 claims description 3
- 102000015600 B melanoma antigen Human genes 0.000 claims description 3
- 108050004877 B melanoma antigen Proteins 0.000 claims description 3
- 108010009575 CD55 Antigens Proteins 0.000 claims description 3
- 108010055167 CD59 Antigens Proteins 0.000 claims description 3
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 3
- 102000011412 Complement 3d Receptors Human genes 0.000 claims description 3
- 108010023729 Complement 3d Receptors Proteins 0.000 claims description 3
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims description 3
- 101700086219 DVA-1 Proteins 0.000 claims description 3
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 3
- 206010065430 HER-2 positive breast cancer Diseases 0.000 claims description 3
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 3
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 3
- 102100015968 IL4R Human genes 0.000 claims description 3
- 108050003490 Insulin-like growth factor Proteins 0.000 claims description 3
- 102000014429 Insulin-like growth factor Human genes 0.000 claims description 3
- 108010017511 Interleukin-13 Receptors Proteins 0.000 claims description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- 201000003533 Leber congenital amaurosis Diseases 0.000 claims description 3
- 210000004759 MCP Anatomy 0.000 claims description 3
- 108010005662 Membrane Cofactor Protein Proteins 0.000 claims description 3
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 claims description 3
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 claims description 3
- 101710003000 ORF1/ORF2 Proteins 0.000 claims description 3
- 101700008337 PSMA Proteins 0.000 claims description 3
- 102100015381 PTGS2 Human genes 0.000 claims description 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 3
- 101710040834 SSO0094 Proteins 0.000 claims description 3
- 102100018596 TEP1 Human genes 0.000 claims description 3
- 101700004103 TEP1 Proteins 0.000 claims description 3
- 102100014223 TGFA Human genes 0.000 claims description 3
- 101710040081 TP1 Proteins 0.000 claims description 3
- LFTYTUAZOPRMMI-CFRASDGPSA-L UDP-N-acetyl-α-D-glucosamine(2-) Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OP([O-])(=O)OP([O-])(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-CFRASDGPSA-L 0.000 claims description 3
- 101710025562 alphaTub85E Proteins 0.000 claims description 3
- 102000006834 complement receptors Human genes 0.000 claims description 3
- 108010047295 complement receptors Proteins 0.000 claims description 3
- 108060003523 dnaK Proteins 0.000 claims description 3
- 101700034648 fgf8b Proteins 0.000 claims description 3
- 101700051903 gph1 Proteins 0.000 claims description 3
- 102000035501 human TERT protein Human genes 0.000 claims description 3
- 108091005810 human TERT protein Proteins 0.000 claims description 3
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 3
- 101710033922 KRAS Proteins 0.000 claims description 2
- 102000005720 Glutathione Transferase family Human genes 0.000 claims 1
- 102000006771 Gonadotropins Human genes 0.000 claims 1
- 108010086677 Gonadotropins Proteins 0.000 claims 1
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 claims 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 1
- 230000003511 endothelial Effects 0.000 claims 1
- 239000002622 gonadotropin Substances 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 210000004027 cells Anatomy 0.000 description 227
- 210000000822 Killer Cells, Natural Anatomy 0.000 description 203
- 230000004044 response Effects 0.000 description 195
- 210000004693 NK cell Anatomy 0.000 description 118
- 230000003053 immunization Effects 0.000 description 107
- 102100008191 CD8A Human genes 0.000 description 106
- 101700054655 CD8A Proteins 0.000 description 106
- 238000002649 immunization Methods 0.000 description 97
- 230000002708 enhancing Effects 0.000 description 82
- 210000004681 Ovum Anatomy 0.000 description 54
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 48
- 230000002147 killing Effects 0.000 description 47
- 241000700605 Viruses Species 0.000 description 43
- 101700086956 IFNG Proteins 0.000 description 38
- 102100016020 IFNG Human genes 0.000 description 38
- 235000001014 amino acid Nutrition 0.000 description 38
- 108050006987 Poxvirus Proteins 0.000 description 36
- 230000015788 innate immune response Effects 0.000 description 32
- 230000001404 mediated Effects 0.000 description 32
- 238000007920 subcutaneous administration Methods 0.000 description 31
- 230000004913 activation Effects 0.000 description 30
- 238000004166 bioassay Methods 0.000 description 30
- 239000007924 injection Substances 0.000 description 28
- 102100005832 CD69 Human genes 0.000 description 27
- 101700080416 CD69 Proteins 0.000 description 27
- 108060007796 SPATA2 Proteins 0.000 description 27
- 230000003612 virological Effects 0.000 description 26
- 229960005486 vaccines Drugs 0.000 description 24
- 230000001939 inductive effect Effects 0.000 description 23
- 230000000259 anti-tumor Effects 0.000 description 22
- 101710009580 NCR1 Proteins 0.000 description 21
- 102100007907 NCR1 Human genes 0.000 description 21
- 230000020411 cell activation Effects 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 20
- 229920001405 Coding region Polymers 0.000 description 19
- 210000000987 Immune System Anatomy 0.000 description 19
- 229920001850 Nucleic acid sequence Polymers 0.000 description 19
- 102100013504 RPL17 Human genes 0.000 description 19
- 238000009175 antibody therapy Methods 0.000 description 19
- 238000002347 injection Methods 0.000 description 19
- 210000004443 Dendritic Cells Anatomy 0.000 description 18
- 230000022534 cell killing Effects 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 17
- 102100005830 CD70 Human genes 0.000 description 16
- 101700017377 CD70 Proteins 0.000 description 16
- 210000004185 Liver Anatomy 0.000 description 16
- 210000000952 Spleen Anatomy 0.000 description 16
- 230000001976 improved Effects 0.000 description 16
- 210000004072 Lung Anatomy 0.000 description 15
- 101710040446 CD40 Proteins 0.000 description 14
- 102100013137 CD40 Human genes 0.000 description 14
- 102100003082 FASLG Human genes 0.000 description 14
- 108010039471 Fas Ligand Protein Proteins 0.000 description 14
- 210000002966 Serum Anatomy 0.000 description 14
- 230000004663 cell proliferation Effects 0.000 description 14
- 238000002648 combination therapy Methods 0.000 description 14
- 238000000684 flow cytometry Methods 0.000 description 14
- 238000010186 staining Methods 0.000 description 14
- 230000004614 tumor growth Effects 0.000 description 14
- 230000003993 interaction Effects 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- 102100015655 BCL2L1 Human genes 0.000 description 12
- 210000004369 Blood Anatomy 0.000 description 12
- 241000700618 Vaccinia virus Species 0.000 description 12
- 230000033289 adaptive immune response Effects 0.000 description 12
- 230000000735 allogeneic Effects 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 201000009910 diseases by infectious agent Diseases 0.000 description 12
- 108010082126 Alanine Transaminase Proteins 0.000 description 11
- 102100010966 GPT Human genes 0.000 description 11
- 238000003260 fluorescence intensity Methods 0.000 description 11
- 230000028993 immune response Effects 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 210000001519 tissues Anatomy 0.000 description 11
- 230000002476 tumorcidal Effects 0.000 description 11
- 238000002255 vaccination Methods 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 241000287828 Gallus gallus Species 0.000 description 10
- 238000004113 cell culture Methods 0.000 description 10
- 238000003780 insertion Methods 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 108060004270 LAG3 Proteins 0.000 description 9
- 210000000265 Leukocytes Anatomy 0.000 description 9
- 108010072668 atezolizumab Proteins 0.000 description 9
- 108010085693 bcl-X Protein Proteins 0.000 description 9
- 230000001419 dependent Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000002744 homologous recombination Methods 0.000 description 9
- 230000003393 splenic Effects 0.000 description 9
- 101700046422 IFNA Proteins 0.000 description 8
- 102000003855 L-lactate dehydrogenases Human genes 0.000 description 8
- 108091000084 L-lactate dehydrogenases Proteins 0.000 description 8
- 210000002540 Macrophages Anatomy 0.000 description 8
- 102100019764 PDCD1 Human genes 0.000 description 8
- 230000003247 decreasing Effects 0.000 description 8
- 108010074109 interleukin-22 Proteins 0.000 description 8
- 230000004807 localization Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 102100016449 CCL5 Human genes 0.000 description 7
- 108030007212 EC 3.4.21.79 Proteins 0.000 description 7
- 102100004391 GZMB Human genes 0.000 description 7
- 210000001616 Monocytes Anatomy 0.000 description 7
- 208000007089 Vaccinia Diseases 0.000 description 7
- 206010046865 Vaccinia virus infection Diseases 0.000 description 7
- 238000010276 construction Methods 0.000 description 7
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000001764 infiltration Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 101710043948 CEACAM7 Proteins 0.000 description 6
- 101700072041 CXCL1 Proteins 0.000 description 6
- 102100018698 CXCL1 Human genes 0.000 description 6
- 101700058542 KLK3 Proteins 0.000 description 6
- 101710027788 NPEPPS Proteins 0.000 description 6
- 101710025567 PSAT1 Proteins 0.000 description 6
- 108091000081 Phosphotransferases Proteins 0.000 description 6
- 102000001253 Protein Kinases Human genes 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 6
- 210000002443 helper T lymphocyte Anatomy 0.000 description 6
- 210000000056 organs Anatomy 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000001225 therapeutic Effects 0.000 description 6
- 108010090838 Alemtuzumab Proteins 0.000 description 5
- 229950002916 Avelumab Drugs 0.000 description 5
- 210000003719 B-Lymphocytes Anatomy 0.000 description 5
- 210000003651 Basophils Anatomy 0.000 description 5
- 102100008428 CCL2 Human genes 0.000 description 5
- 101700006000 CCL2 Proteins 0.000 description 5
- 101700063377 CCL5 Proteins 0.000 description 5
- 102100006400 CSF2 Human genes 0.000 description 5
- 102100009641 CXCL10 Human genes 0.000 description 5
- 101710032181 CXCL10 Proteins 0.000 description 5
- 229940112129 Campath Drugs 0.000 description 5
- 108010022830 Cetuximab Proteins 0.000 description 5
- 210000004436 Chromosomes, Artificial, Bacterial Anatomy 0.000 description 5
- 229940094732 Darzalex Drugs 0.000 description 5
- 210000003979 Eosinophils Anatomy 0.000 description 5
- 229940082789 Erbitux Drugs 0.000 description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
- 229940022353 Herceptin Drugs 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 210000000138 Mast Cells Anatomy 0.000 description 5
- 210000000440 Neutrophils Anatomy 0.000 description 5
- 229960002450 Ofatumumab Drugs 0.000 description 5
- LZMPYSIUWPEIRA-XFXZXTDPSA-N Ofatumumab Chemical compound N1=C2C=3COCCC=3N=CC2=N\C1=C1\NOC=C1 LZMPYSIUWPEIRA-XFXZXTDPSA-N 0.000 description 5
- 108010061219 Panitumumab Proteins 0.000 description 5
- 229940039551 Perjeta Drugs 0.000 description 5
- 108010001645 Rituximab Proteins 0.000 description 5
- 101710038663 SELL Proteins 0.000 description 5
- 102100008254 SELL Human genes 0.000 description 5
- 102100015249 VEGFA Human genes 0.000 description 5
- 229960000548 alemtuzumab Drugs 0.000 description 5
- 230000002494 anti-cea Effects 0.000 description 5
- 108010010826 avelumab Proteins 0.000 description 5
- 230000000903 blocking Effects 0.000 description 5
- 229960005395 cetuximab Drugs 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- 108010031324 daratumumab Proteins 0.000 description 5
- 229960002204 daratumumab Drugs 0.000 description 5
- 229960004497 dinutuximab Drugs 0.000 description 5
- 108091003638 dinutuximab Proteins 0.000 description 5
- 210000003162 effector T lymphocyte Anatomy 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 108010052070 ofatumumab Proteins 0.000 description 5
- 229960001972 panitumumab Drugs 0.000 description 5
- 230000003389 potentiating Effects 0.000 description 5
- 229960004641 rituximab Drugs 0.000 description 5
- 229960005267 tositumomab Drugs 0.000 description 5
- 102100007788 APC Human genes 0.000 description 4
- 101700050663 ART1 Proteins 0.000 description 4
- 241000700663 Avipoxvirus Species 0.000 description 4
- 102100016450 CCL7 Human genes 0.000 description 4
- 101700044004 CCL7 Proteins 0.000 description 4
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 4
- 101700054183 CTLA4 Proteins 0.000 description 4
- 102100005310 CTLA4 Human genes 0.000 description 4
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 4
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 4
- 229950009791 Durvalumab Drugs 0.000 description 4
- 101700075959 EOMES Proteins 0.000 description 4
- 210000001161 Embryo, Mammalian Anatomy 0.000 description 4
- 101700064140 FOXP3 Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 229920001204 Intergenic region Polymers 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108010089187 Ipilimumab Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229950000035 Mirvetuximab soravtansine Drugs 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 229950003804 Siplizumab Drugs 0.000 description 4
- 229960003852 atezolizumab Drugs 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 108010016436 durvalumab Proteins 0.000 description 4
- 230000001506 immunosuppresive Effects 0.000 description 4
- 229960005386 ipilimumab Drugs 0.000 description 4
- 108010008856 mirvetuximab soravtansine Proteins 0.000 description 4
- 229920000023 polynucleotide Polymers 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 210000003289 regulatory T cell Anatomy 0.000 description 4
- 108010073705 siplizumab Proteins 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 101710032374 BCL2L1 Proteins 0.000 description 3
- 101710003804 CD40LG Proteins 0.000 description 3
- 241000178270 Canarypox virus Species 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 102100020039 HPGDS Human genes 0.000 description 3
- 206010022114 Injury Diseases 0.000 description 3
- 210000001165 Lymph Nodes Anatomy 0.000 description 3
- 108060004839 MIC Proteins 0.000 description 3
- 102100006037 MUC1 Human genes 0.000 description 3
- 101700052761 MUC1 Proteins 0.000 description 3
- 102000015728 Mucins Human genes 0.000 description 3
- 101710033916 NRAS Proteins 0.000 description 3
- 102100001119 NRAS Human genes 0.000 description 3
- 102100007015 SERPINE1 Human genes 0.000 description 3
- 101700019638 TRPC4 Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000003213 activating Effects 0.000 description 3
- 230000000240 adjuvant Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 239000006143 cell culture media Substances 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 230000002068 genetic Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000002934 lysing Effects 0.000 description 3
- 238000007898 magnetic cell sorting Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000003071 memory T lymphocyte Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006011 modification reaction Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000002516 postimmunization Effects 0.000 description 3
- 230000001105 regulatory Effects 0.000 description 3
- 230000003362 replicative Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 101710042243 trpE(G) Proteins 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- 108010082808 4-1BB Ligand Proteins 0.000 description 2
- 108010032595 Antibody Binding Sites Proteins 0.000 description 2
- 206010059512 Apoptosis Diseases 0.000 description 2
- 108010008778 Brachyury protein Proteins 0.000 description 2
- 102100003268 CD14 Human genes 0.000 description 2
- 101700027514 CD14 Proteins 0.000 description 2
- 108010084313 CD58 Antigens Proteins 0.000 description 2
- 101700002874 CD72 Proteins 0.000 description 2
- 102100019446 CD72 Human genes 0.000 description 2
- 102100006435 CSF3 Human genes 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 108010055166 Chemokine CCL5 Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000712469 Fowl plague virus Species 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 229940084986 Human Chorionic Gonadotropin Drugs 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006822 Human Serum Albumin Proteins 0.000 description 2
- 102100004115 ICAM1 Human genes 0.000 description 2
- 102000018358 Immunoglobulins Human genes 0.000 description 2
- 108060003951 Immunoglobulins Proteins 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 2
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102100002396 MRPS30 Human genes 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108010033725 Recombinant Proteins Proteins 0.000 description 2
- 102000007312 Recombinant Proteins Human genes 0.000 description 2
- 102100018674 TBXT Human genes 0.000 description 2
- 102100011846 TNFSF4 Human genes 0.000 description 2
- 101710025695 TNFSF4 Proteins 0.000 description 2
- 102100003084 TNFSF9 Human genes 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptors Proteins 0.000 description 2
- 102000003298 Tumor Necrosis Factor Receptors Human genes 0.000 description 2
- 230000003044 adaptive Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000001270 agonistic Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000002424 anti-apoptotic Effects 0.000 description 2
- 230000007961 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent Effects 0.000 description 2
- 230000005164 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000001580 bacterial Effects 0.000 description 2
- 238000009566 cancer vaccine Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000002559 cytogenic Effects 0.000 description 2
- 230000001809 detectable Effects 0.000 description 2
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001024 immunotherapeutic Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000002458 infectious Effects 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 108010045030 monoclonal antibodies Proteins 0.000 description 2
- 102000005614 monoclonal antibodies Human genes 0.000 description 2
- 230000000877 morphologic Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 description 2
- 230000000770 pro-inflamatory Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002062 proliferating Effects 0.000 description 2
- 230000002035 prolonged Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002195 synergetic Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000003442 weekly Effects 0.000 description 2
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- QXDYJUSFCUKOQD-UHFFFAOYSA-N 2-(2-methylprop-2-enoyloxy)ethyl 2-bromo-2-methylpropanoate Chemical compound CC(=C)C(=O)OCCOC(=O)C(C)(C)Br QXDYJUSFCUKOQD-UHFFFAOYSA-N 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102100007326 BIRC5 Human genes 0.000 description 1
- 101710042656 BQ2027_MB1231C Proteins 0.000 description 1
- 241001098553 Boreus hyemalis Species 0.000 description 1
- 102000002086 C-type lectin-like Human genes 0.000 description 1
- 108050009406 C-type lectin-like Proteins 0.000 description 1
- 101710012053 CD274 Proteins 0.000 description 1
- 102100007290 CD274 Human genes 0.000 description 1
- 102100005828 CD5 Human genes 0.000 description 1
- 101700066525 CD5 Proteins 0.000 description 1
- 210000001266 CD8-Positive T-Lymphocytes Anatomy 0.000 description 1
- 101700016900 CDH1 Proteins 0.000 description 1
- 102100004728 CDH1 Human genes 0.000 description 1
- 210000003837 Chick Embryo Anatomy 0.000 description 1
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 1
- 108009000280 Complement Activation Proteins 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- 210000001787 Dendrites Anatomy 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000001301 EGF receptors Human genes 0.000 description 1
- 108060006698 EGF receptors Proteins 0.000 description 1
- 102000027760 ERBB2 Human genes 0.000 description 1
- 102000027776 ERBB3 Human genes 0.000 description 1
- 101700041204 ERBB3 Proteins 0.000 description 1
- 102100009851 ERBB4 Human genes 0.000 description 1
- 101700023619 ERBB4 Proteins 0.000 description 1
- 101710003440 FCGR1A Proteins 0.000 description 1
- 102100015540 FCGR1A Human genes 0.000 description 1
- 101700010580 FLO11 Proteins 0.000 description 1
- 230000035693 Fab Effects 0.000 description 1
- 206010016629 Fibroma Diseases 0.000 description 1
- 102100011343 GLB1 Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 206010066896 HER-2 positive gastric cancer Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101710006547 Hsp70Ab Proteins 0.000 description 1
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 1
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 1
- 102100005026 IL21 Human genes 0.000 description 1
- 229960000310 ISOLEUCINE Drugs 0.000 description 1
- 241001562081 Ikeda Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 229940047124 Interferons Drugs 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 229920002459 Intron Polymers 0.000 description 1
- 210000002510 Keratinocytes Anatomy 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 101700048185 LAMP1 Proteins 0.000 description 1
- 102100005918 LAMP1 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 1
- 210000002751 Lymph Anatomy 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000035633 Metabolized Effects 0.000 description 1
- 206010061289 Metastatic neoplasm Diseases 0.000 description 1
- 125000000534 N(2)-L-lysino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C([H])([H])C(C([H])([H])N([H])[H])([H])[H] 0.000 description 1
- 102100007544 NCAM1 Human genes 0.000 description 1
- 101700077124 NCAM1 Proteins 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- 241000700629 Orthopoxvirus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102100012888 PLAU Human genes 0.000 description 1
- 101710010583 PLAU Proteins 0.000 description 1
- 101700068068 PSM Proteins 0.000 description 1
- 241000287882 Pavo Species 0.000 description 1
- 241001569977 Penguinpox virus Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000700667 Pigeonpox virus Species 0.000 description 1
- 229920000096 Plastarch material Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 241000287531 Psittacidae Species 0.000 description 1
- 241000569181 Quailpox virus Species 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000724205 Rice stripe tenuivirus Species 0.000 description 1
- 101700016899 SH2B1 Proteins 0.000 description 1
- 102100018868 SIGLEC1 Human genes 0.000 description 1
- 101710017790 SIGLEC1 Proteins 0.000 description 1
- 230000037165 Serum Concentration Effects 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 229920000978 Start codon Polymers 0.000 description 1
- 241000287181 Sturnus vulgaris Species 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 102100011911 TRAP1 Human genes 0.000 description 1
- 108060008602 TRAP1 Proteins 0.000 description 1
- 101700000513 TYRP1 Proteins 0.000 description 1
- 241001067453 Therion Species 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 241000385708 Turkeypox virus Species 0.000 description 1
- 241000587120 Vaccinia virus Ankara Species 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 206010047461 Viral infection Diseases 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 230000001028 anti-proliferant Effects 0.000 description 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000511 arginine group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000002238 attenuated Effects 0.000 description 1
- 230000003190 augmentative Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 201000006082 chickenpox Diseases 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000001143 conditioned Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000000139 costimulatory Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000000779 depleting Effects 0.000 description 1
- 230000000994 depressed Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000002222 downregulating Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002257 embryonic structures Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 description 1
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 102000034387 fluorescent proteins Human genes 0.000 description 1
- 108091006031 fluorescent proteins Proteins 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000004964 innate lymphoid cells Anatomy 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000000527 lymphocytic Effects 0.000 description 1
- 230000002101 lytic Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 media Substances 0.000 description 1
- 230000001394 metastastic Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 229960000060 monoclonal antibodies Drugs 0.000 description 1
- 231100001092 no hepatotoxicity Toxicity 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic Effects 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 1
- 229920003259 poly(silylenemethylene) Polymers 0.000 description 1
- 230000001402 polyadenylating Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 230000000644 propagated Effects 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108060006962 recR Proteins 0.000 description 1
- 230000033300 receptor internalization Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 230000001177 retroviral Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000000630 rising Effects 0.000 description 1
- 101710040918 shg Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 108020000411 toll-like receptors Proteins 0.000 description 1
- 102000002689 toll-like receptors Human genes 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002103 transcriptional Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17187824.2 | 2017-08-24 | ||
| EP17187824 | 2017-08-24 | ||
| PCT/EP2018/072789 WO2019038388A1 (fr) | 2017-08-24 | 2018-08-23 | Polythérapie pour le traitement du cancer par administration intraveineuse d'un mva de recombinaison et d'un anticorps |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020531524A JP2020531524A (ja) | 2020-11-05 |
| JP2020531524A5 JP2020531524A5 (fr) | 2021-09-09 |
| JPWO2019038388A5 true JPWO2019038388A5 (fr) | 2022-09-07 |
| JP7202362B2 JP7202362B2 (ja) | 2023-01-11 |
Family
ID=59702586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511314A Active JP7202362B2 (ja) | 2017-08-24 | 2018-08-23 | 組み換えｍｖａ及び抗体の静脈内投与を用いた、がん治療のための併用療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11273211B2 (fr) |
| EP (1) | EP3691675A1 (fr) |
| JP (1) | JP7202362B2 (fr) |
| KR (1) | KR20200044000A (fr) |
| CN (1) | CN111050790A (fr) |
| AU (1) | AU2018320417A1 (fr) |
| BR (1) | BR112020003669A2 (fr) |
| CA (1) | CA3073310A1 (fr) |
| IL (1) | IL272546B2 (fr) |
| MX (1) | MX2020001856A (fr) |
| SG (1) | SG11202001115TA (fr) |
| WO (1) | WO2019038388A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| PE20221182A1 (es) | 2019-11-18 | 2022-08-05 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
| US20240182568A1 (en) * | 2021-03-10 | 2024-06-06 | University Of Iowa Research Foundation | Methods of enhancing antibody therapies |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766598A (en) | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
| EP0954593A1 (fr) | 1996-07-25 | 1999-11-10 | Therion Biologics Corporation | Poxvirus recombinant pour l'immunisation contre des antigenes associes aux tumeurs |
| EP1865065A1 (fr) * | 1998-12-09 | 2007-12-12 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Vecteur recombinant exprimant plusieurs molécules costimulantes et ses utilisations |
| ES2256323T5 (es) | 2000-11-23 | 2016-11-21 | Bavarian Nordic A/S | Variante del virus Vaccinia Ankara Modificado |
| CA2468258C (fr) | 2001-11-30 | 2011-10-11 | Jeffrey Schlom | Peptides agonistes d'antigenes specifiques de la prostate et leurs utilisations |
| CN102409063A (zh) | 2001-12-04 | 2012-04-11 | 巴法里安诺迪克有限公司 | 黄病毒ns1亚单位疫苗 |
| RU2397249C2 (ru) | 2003-07-21 | 2010-08-20 | Иституто Ди Ричерке Ди Биолоджиа Молеколаре П Анджелетти Спа | СИНТЕТИЧЕСКАЯ МОЛЕКУЛА НУКЛЕИНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР ДЛЯ КЛЕТОК МЛЕКОПИТАЮЩЕГО, КЛЕТКА МЛЕКОПИТАЮЩЕГО ХОЗЯИНА И СПОСОБ ЭКСПРЕССИИ ЧЕЛОВЕЧЕСКОГО БЕЛКА АНТИГЕНА ЭПИДЕРМАЛЬНОГО ФАКТОРА РОСТА-2 (HER2/neu) ИЛИ ЕГО УКОРОЧЕННОЙ ФОРМЫ |
| CA2741724C (fr) | 2008-11-27 | 2016-10-04 | Bavarian Nordic A/S | Promoteurs pour expression virale recombinante |
| US8394385B2 (en) | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| JP5759980B2 (ja) * | 2009-04-17 | 2015-08-05 | グローブイミューン，インコーポレイテッド | 癌および感染症に対する免疫療法組成物の組み合わせ |
| EP2864487B1 (fr) | 2012-06-22 | 2018-12-05 | Bavarian Nordic A/S | Vecteurs poxviraux servant de faible réponse anticorps après une première immunisation d'amorçage |
| WO2014037124A1 (fr) | 2012-09-04 | 2014-03-13 | Bavarian Nordic A/S | Procédés et compositions pour l'amélioration de réponses immunitaires à la vaccine |
| WO2014043535A1 (fr) * | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions destinées à traiter le cancer |
| WO2014043518A1 (fr) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Protéine brachyury, vecteurs non levure, non poxvirus, codant pour la protéine brachyury, et leur utilisation |
| JP2016502507A (ja) | 2012-10-19 | 2016-01-28 | バヴァリアン・ノルディック・インコーポレイテッド | 癌治療のための組成物および方法 |
| SG10201704657WA (en) | 2012-10-28 | 2017-07-28 | Bavarian Nordic As | Pr13.5 promoter for robust t-cell and antibody responses |
| US9725494B2 (en) * | 2013-05-17 | 2017-08-08 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Soluble CD27 (sCD27) and the use thereof |
| CA2928199A1 (fr) * | 2013-11-05 | 2015-05-14 | Bavarian Nordic A/S | Polytherapie pour le traitement du cancer a l'aide d'un poxvirus exprimant un antigene tumoral et d'un antagoniste et/ou agoniste d'un inhibiteur de point de controle immunitaire |
| LT3074517T (lt) * | 2013-11-28 | 2021-11-25 | Bavarian Nordic A/S | Kompozicijos ir būdai, skirti sukelti padidintą imuninį atsaką, naudojant raupų viruso vektorius |
| KR102499737B1 (ko) * | 2014-05-13 | 2023-02-13 | 버베리안 노딕 에이/에스 | 종양 항원을 발현하는 재조합 폭스바이러스 및 면역 체크포인트 분자 길항제 또는 효현제로 암을 치료하기 위한 복합 요법 |
| EP3166646A4 (fr) | 2014-07-07 | 2018-03-07 | Duke University | Vaccins contre un isoforme oncogène d'her2 (erbb2) et leurs méthodes d'utilisation |
| JP2017530114A (ja) * | 2014-09-26 | 2017-10-12 | バヴァリアン・ノルディック・アクティーゼルスカブ | フラジェリンをコードする組み換えｍｖａによる鼻腔内免疫のための方法と組成物 |
| US11753652B2 (en) | 2015-07-31 | 2023-09-12 | Bavarian Nordic A/S | Cassette encoding a FPV/brachyury fusion protein |
| US20220000997A1 (en) * | 2019-02-19 | 2022-01-06 | Bavarian Nordic A/S | Therapy for Treating Cancer with an Intratumoral or Intravenous Administration of a Recombinant MVA Encoding 4-1BBL (CD137L) and/or CD40L |
| US20230059344A1 (en) * | 2019-11-20 | 2023-02-23 | Bavarian Nordic A/S | Medical Uses of 4-1BBL Adjuvanted Recombinant Modified Vaccinia Virus Ankara (MVA) |
| WO2023118508A1 (fr) * | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Virus mva recombinants pour administration intrapéritonéale pour le traitement du cancer |
-
2018
- 2018-08-23 CA CA3073310A patent/CA3073310A1/fr active Pending
- 2018-08-23 SG SG11202001115TA patent/SG11202001115TA/en unknown
- 2018-08-23 WO PCT/EP2018/072789 patent/WO2019038388A1/fr unknown
- 2018-08-23 JP JP2020511314A patent/JP7202362B2/ja active Active
- 2018-08-23 IL IL272546A patent/IL272546B2/en unknown
- 2018-08-23 AU AU2018320417A patent/AU2018320417A1/en active Pending
- 2018-08-23 BR BR112020003669-2A patent/BR112020003669A2/pt unknown
- 2018-08-23 US US16/641,236 patent/US11273211B2/en active Active
- 2018-08-23 CN CN201880054776.8A patent/CN111050790A/zh active Pending
- 2018-08-23 EP EP18756447.1A patent/EP3691675A1/fr active Pending
- 2018-08-23 KR KR1020207005076A patent/KR20200044000A/ko not_active Application Discontinuation
- 2018-08-23 MX MX2020001856A patent/MX2020001856A/es unknown
-
2022
- 2022-03-14 US US17/693,716 patent/US11723964B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210128706A1 (en) | Vaccine composition | |
| US11723964B2 (en) | Combination therapy for treating cancer with an antibody and intravenous administration of a recombinant MVA | |
| CA3119503A1 (fr) | Therapie pour le traitement du cancer par une administration intratumorale et/ou intraveineuse d'un mva recombinant codant pour 4-1bbl (cd137l) et/ou cd40l | |
| JP2019528755A (ja) | ポックスウイルス内における導入遺伝子の安定性を向上させるための組成物及び方法 | |
| JP2022512595A (ja) | 組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法 | |
| US20230190922A1 (en) | Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer | |
| WO2023118508A1 (fr) | Virus mva recombinants pour administration intrapéritonéale pour le traitement du cancer | |
| JPWO2019038388A5 (fr) | ||
| RU2795103C2 (ru) | Комбинированная терапия для лечения рака путем внутривенного введения рекомбинантного mva и антитела | |
| US20220000997A1 (en) | Therapy for Treating Cancer with an Intratumoral or Intravenous Administration of a Recombinant MVA Encoding 4-1BBL (CD137L) and/or CD40L | |
| WO2023118563A1 (fr) | Thérapie pour moduler une réponse immunitaire au moyen d'un mva recombinant codant pour il-12 | |
| AU2022422563A1 (en) | Therapy for modulating immune response with recombinant mva encoding il-12 | |
| WO2024062098A1 (fr) | Virus de la paraviccine recombinant codant pour l'interleukine-12 |